MorphoSys has received a clinical milestone payment from Bayer, relating to the launch of a Phase II clinical trial on a candidate treatment for rare cancer mesothelioma. The candidate, anetumab ravtansine (BAY 94-9343), was developed by Bayer using the MorphoSys Human Combinatorial Antibody Library (HuCAL) technology, which involves the in-vitro generation of distinct fully human antibodies. Anetumab ravtansine was the fourth antibody developed using the HuCAL technology platform to move into decisive phases of clinical development.